|Systematic (IUPAC) name|
|Mol. mass||302.34 g/mol|
| (what is this?)
Safinamide (EMD 1195686) is a candidate drug against Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.
Methods of action
Parkinson and RLS relevant mechanisms
Safinamide is a monoamine oxidase B inhibitor, reducing degradation of dopamine, and a glutamate release inhibitor. It also seems to inhibit dopamine reuptake. Additionally, safinamide blocks sodium and calcium channels.
- Fariello, RG (2007). "Safinamide". Neurotherapeutics 4 (1): 110–116. doi:10.1016/j.nurt.2006.11.011. PMID 17199024.
- Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)
- Merck Returns Rights for Safinamide to Newron, 21 October 2011.
- Chazot, PL (2007). "Drug evaluation: Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome". Current opinion in investigational drugs 8 (7): 570–579. PMID 17659477.
- Caccia, C; Maj, R; Calabresi, M; Maestroni, S; Faravelli, L; Curatolo, L; Salvati, P; Fariello, RG (2006). "Safinamide: From molecular targets to a new anti-Parkinson drug". Neurology 67 (7 Suppl 2): S18–23. PMID 17030736.
- Merck Serono: Vielversprechende Daten zur kognitiven Wirkung von Safinamid bei Parkinson im Frühstadium. (German) 8 June 2007.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|